ASBMR Responds to Final ICER Report on Cost Effectiveness of Anabolic Agents for Osteoporosis
Date: July 27, 2017
The Institute for Clinical and Economic Review (ICER) released last week its final evidence report assessing the comparative clinical effectiveness and cost of the osteoporosis drug therapies teriparatide and abaloparatide. The report includes a summary of a June 30, 2017 public meeting where ASBMR Professional Practice Committee Chair, Benjamin Leder, MD, testified to discuss concerns about the evidence being used for the report. Read the full ASBMR statement here.